Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

818.03 -4.93 (-0.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 487,711
Open 827.00
Bid (Size) 811.00 (1)
Ask (Size) 822.00 (1)
Prev. Close 822.96
Today's Range 808.90 - 833.28
52wk Range 668.00 - 847.50
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
If the biotech does split its stock, it will be a first for the company. 
Via The Motley Fool

Performance

YTD
+13.54%
+13.54%
1 Month
-0.59%
-0.59%
3 Month
+13.92%
+13.92%
6 Month
-0.99%
-0.99%
1 Year
+11.28%
+11.28%

More News

Read More
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Examining the Quality Attributes of NASDAQ:REGN.
Via Chartmill
Analyst Expectations for Regeneron Pharmaceuticals's Future
Via Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/19 Morning Trading
Via Investor Brand Network
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Three Of Our Top Picks For Your Healthcare Portfolio
Via Talk Markets
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Check Out What Whales Are Doing With REGN
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Via MarketBeat
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
Via The Motley Fool
Exposures Product Safety
3 Stocks to Buy to Ride Europe’s Coming Market Surge
Via InvestorPlace
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/8 Morning Trading
Via Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023
Via Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
New to Investing? Here's How You Can Get Started With $500.
Via The Motley Fool
3 Unstoppable Growth Stocks to Buy Right Now
Via The Motley Fool
Regeneron Provides Update on Planned Chief Financial Officer Transition
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Updates to Board of Directors
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.